A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).
Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.
The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
The main inclusion criteria include but are not limited to the following:
The main exclusion criteria include but are not limited to the following
Trialsites@msd.com1-888-577-8839
Scottsdale, Arizona 85255, United States
602-613-5473
Redlands, California 92374, United States
St. Petersburg, Florida 33711, United States
Wildwood, Florida 34785, United States
Albuquerque, New Mexico 87109, United States
Hauppauge, New York 11788, United States
Winston-Salem, North Carolina 27103, United States
Bluffton, South Carolina 29910, United States
Charleston, South Carolina 29414, United States
Mt. Pleasant, South Carolina 29464, United States
Rosario, Santa Fe Province S2000DLA, Argentina
Rosario, Santa Fe Province S2000DSK, Argentina
Buenos Aires, C1023AAQ, Argentina
Cdad. Autónoma de Buenos Aires, 1008, Argentina
+54 9 11 7123 -9245
Cdad. Autónoma de Buenos Aires, C1428, Argentina
+54 9 11 5344-1235
Córdoba, 5000, Argentina
Barcelona, 08035, Spain
Binnigen, CH-4102, Switzerland
(+) 41 61426 6079
Lausanne, CH-1004, Switzerland
479-234-4499
479-408-4470
818-246-2560
209-521-6173
951-788-0222
916-974-9279
916-339-3650
407-775-7495
954-776-6880
352-300-8412
206-338-0248
561-408-0853
954-635-2861
727-323-0077
850-942-6700
616-438-9395
813-987-2000
407-473-5596
872-222-0139
217-528-7541
317-571-1501
317-805-2152
301-665-1712
616-438-9395
601-255-0736
601-981-4091
215-928-3092
505-393-7483
516-466-0390
315-445-8166
336-369-7160
919-782-8038
336-397-9216
513-569-3462
918-395-0872
971-865-2781
503-296-6484
516-466-0390
803-867-7058
843-278-9938
843-972-3857
843-763-4466
901-683-0399
325-690-4414
806-350-1113
682-433-5453
512-454-5851
512-451-0103
281-249-9076
800-695-6941
469-560-0177
817-865-6800
713-524-3434
682-703-4318
801-312-2020
434-947-3984
360-205-5417
509-990-9913
304-346-4400
715-261-8500
+54 9 341 612-9382
+54 9 341 617-3017
+54 9 341 361-8977
54 911 5161-5949
+54 9 11 5995-6857
+54 9 11 5994-4371
+54 9 11 4813-7795
+54 9 11 2282-8104
115857-7777
+54 9 354 747-7922
+54 9 295 452-7642
+54 9 261 509-7842
+54 9 261 501-1035
+54 9 387 605-6975
+54 9 387 605-6975
+54 9 387 605-6975
+61 2 9959 0053
+61 2 9570 1622
+61 422 466 330
+ 61 2 9635 7077
+61 2 9746 2988
+61 2 9382 7379
+61 2 9570 1522
+372 56207596
+972 (0)54-8002038
+972 (0)50-2061061
+972 (0)50-8154556
+972 (0)54-5510093
+972 (0)52-5659744
+972 (0)53-2227937
+972 (0)50-6316266
+972 (0)54-7541053
37129106879
(+) 37 126 520 449
(+) 37126160330
48606616655
+34 932 095 311 ext. 2303
(+34) 674108369
(+34)911916000
(+) 41791393928
(+) 41 31 311 12 22
(+) 41 216 268 166
(+) 41 44 416 42 80
447929873467
44208 453 2711